OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

OXFORD BIOMEDICA LS-,50/  GB00BDFBVT43  /

Düsseldorf
10/10/2024  19:32:00 Chg. 0.000 Volume Bid19:32:03 Ask19:32:03 Market Capitalization Dividend Y. P/E Ratio
4.460EUR 0.00% 0
Turnover: 0.000		 4.460Bid Size: 500 4.740Ask Size: 500 366.47 mill.EUR - -
GlobeNewswire 02/09 Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
GlobeNewswire 27/08 Oxford Biomedica to host a free webinar showcasing its AAV expertise
GlobeNewswire 08/08 Aligos Therapeutics Strengthens Board with Two New Independent Directors
GlobeNewswire 08/08 Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
GlobeNewswire 06/08 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 25/07 Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
GlobeNewswire 17/07 Oxford Biomedica announces CFO transition
GlobeNewswire 01/04 Autolus Therapeutics Announces Changes to its Board of Directors
GlobeNewswire 18/03 Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire 06/03 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire 05/03 Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire 29/01 Oxford Biomedica completes acquisition of ABL Europe
GlobeNewswire 23/01 Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire 07/01 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire 03/01 Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire 07/12/2023 Business Update
GlobeNewswire 04/12/2023 Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire 16/11/2023 Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire 14/11/2023 Homology Medicines Reports Third Quarter 2023 Financial Results
GlobeNewswire 09/11/2023 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 20/09/2023 Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire 20/09/2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire 07/09/2023 Oxford Biomedica to host webinar showcasing the TetraVecta™ system
GlobeNewswire 23/03/2022 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire 17/03/2022 Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...